Skip to main content
RemeGen Co., Ltd. logo

RemeGen Co., Ltd. — Investor Relations & Filings

Ticker · 9995 ISIN · CNE1000048G6 LEI · 300300M9HCX4TFAD4I10 HKEX Manufacturing
Open in API
Filings indexed 1,623 across all filing types
Latest filing 2026-05-18 Board/Management Inform…
Country CN China
Listing HKEX 9995

About RemeGen Co., Ltd.

http://www.remegen.com

RemeGen Co., Ltd. is a biopharmaceutical company dedicated to the discovery, development, production, and commercialization of innovative biological drugs. The company focuses on creating first-in-class and best-in-class therapeutics to address significant unmet clinical needs, particularly in the critical therapeutic areas of autoimmune diseases, oncology, and ophthalmology. RemeGen utilizes proprietary technology platforms capable of discovering, screening, and developing new molecules and efficiently optimizing production processes. Its pipeline includes a series of innovative biologics, such as Telitacicept, and features 8 clinical pipelines, over 40 clinical trials, and more than 600 patent applications, demonstrating a strong commitment to R&D and innovation in biopharmaceuticals.

Recent filings

Filing Released Lang Actions
荣昌生物董事会提名委员会关于第三届董事会独立董事候选人的审核意见
Board/Management Information Classification · 98% confidence The document is an opinion from the Board’s Nomination Committee reviewing and nominating candidates for the company’s independent directors. It relates to changes in the company’s board composition and provides nomination details. This fits the “Board/Management Information” category (MANG).
2026-05-18 Chinese
荣昌生物信息披露管理制度
Governance Information Classification · 96% confidence The document is the internal "Information Disclosure Management System" of the company, setting out its policies, procedures, and governance rules for disclosures under various stock exchange and regulatory regulations. It is not a specific event announcement, financial results, or transaction notice, but rather a corporate governance manual detailing internal rules. This matches the Governance Information (CGR) category.
2026-05-18 Chinese
华泰联合证券有限责任公司关于荣昌生物制药（烟台）股份有限公司部分募投项目子项目变更及金额调整的核查意见
Regulatory Filings Classification · 85% confidence The document is a sponsor’s verification opinion (“核查意见”) by Huatai United Securities on adjustments to IPO fundraising projects and the use of proceeds. It is a regulatory compliance disclosure under the Shanghai Stock Exchange’s continuous supervision rules, not a financial report (10-K, IR, etc.) nor an earnings release or dividend notice. It is also not merely an announcement of a report publication. As a fallback for miscellaneous regulatory filings that do not fit other categories, it should be classified as Regulatory Filings (RNS).
2026-05-18 Chinese
荣昌生物董事、高级管理人员薪酬管理制度
Governance Information Classification · 95% confidence The document is titled “董事、高级管理人员薪酬管理制度” (Board and Senior Management Compensation Management System) and sets out the internal rules, principles, organizational structure, roles, and procedures for determining and managing directors’ and executives’ remuneration. It is a governance policy detailing the company’s internal rules and board committee functions rather than an actual financial report, announcement of financial results, or a proxy solicitation. Therefore, it falls under Governance Information (CGR).
2026-05-18 Chinese
荣昌生物董事会议事规则
Governance Information Classification · 96% confidence The document is the “Board Meeting Rules” (“董事会议事规则”) for the company, setting out the internal governance framework, board composition, decision procedures, committee structures, meeting protocols, and related organizational rules. It is not an announcement of a particular meeting, financial report, or transaction, but rather a detailed governance manual. This matches the “Governance Information” category.
2026-05-18 Chinese
H股公告
Regulatory Filings Classification · 85% confidence The document is a Hong Kong Exchange announcement disclosing a “disclosable transaction” under Listing Rule 14 about using idle funds to purchase wealth management products. It is not an earnings release, financial report, management change, share issuance or buyback, dividend notice, or other specific category. It is a general regulatory/compliance announcement required by the stock exchange. Therefore, it falls into the fallback “Regulatory Filings” category.
2026-05-15 Chinese

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.